Belgian Severe Asthma Registry. Which Biotherapy to Choose According to Inflammatory Characteristics?

According to Belgian reimbursement criteria for anti-IgE (total IgE, 76-700) and anti-IL5 (>=300/mm3), 44% of patients are potentially eligible for anti-IL5, while among candidates to anti-IgE, 50% are eligible for both biotherapy (table-figure).

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2017-02, Vol.139 (2), p.AB11-AB11
Main Authors: Schleich, Florence N., MD, PhD, Brusselle, Guy, MD, PhD, Louis, Renaud, Vandenplas, Olivier, Michils, Alain, MD, Pilette, Charles, Peche, Rudi, MD, Joos, Guy F.P., MD, PhD
Format: Article
Language:English
Subjects:
Allergies
Allergy and Immunology
Asthma
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to Belgian reimbursement criteria for anti-IgE (total IgE, 76-700) and anti-IL5 (>=300/mm3), 44% of patients are potentially eligible for anti-IL5, while among candidates to anti-IgE, 50% are eligible for both biotherapy (table-figure).
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2016.12.091